Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIN0SV)

• Drug Name: GSK2269557 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 49784002
  CAS Number: CAS 1254036-71-9
  TTD Drug ID: DMIN0SV

Molecule-Related Drug Atlas

Drug(s) Targeting Stress-activated protein kinase (p38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-07265803	DM3E6Q4	Dilated cardiomyopathy	BC43.0	Phase 3	[3]
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[4]
BMS-582949	DMGYXFP	Atherosclerosis	BD40	Phase 2	[5]
AZD7624	DMEW3K9	Chronic obstructive pulmonary disease	CA22	Phase 2	[6]
TAK-715	DMZKPI8	Rheumatoid arthritis	FA20	Phase 2	[7]
MW150	DMBRVXB	Alzheimer disease	8A20	Phase 2	[8]
LY-2228820	DMHXTNW	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
PUR1800	DM6H10N	Chronic obstructive pulmonary disease	CA22	Phase 1	[10]
ARRY-614	DMXD93K	Arthritis	FA20	Discontinued in Phase 1	[11]
TA-5493	DMFES2K	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stress-activated protein kinase (p38)	TTWELHI	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02522299) A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation.
• [2] Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
• [3] Clinical pipeline report, company report or official report of Pfizer
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
• [6] Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
• [7] Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
• [8] p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
• [10] Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
• [11] Cmpany report (Arraybiopharma)
• [12] US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.